Results 11 to 20 of about 28,367 (198)
Microbiology SpectrumBedaquiline is a key drug recommended by the WHO for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB, and its use could potentially shorten treatment duration with improved outcomes.
Faiqa Rashid +3 more
doaj +2 more sources
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE.
PLoS ONE, 2019 Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical
Malancha Karmakar +5 more
doaj +2 more sources
PLoS Medicine, 2016 BackgroundNew drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established.
Amber Kunkel +2 more
doaj +2 more sources
International Journal of MycobacteriologyBackground: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono +5 more
doaj +2 more sources
Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
Emerging Infectious DiseasesBedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and ...
Gunar Günther +9 more
doaj +2 more sources
Infection and Drug Resistance, 2023 Enyu Tong,1,* Ying Zhou,1,* Zhengwei Liu,2 Yelei Zhu,2 Mingwu Zhang,2 Kunyang Wu,2 Junhang Pan,2 Jianmin Jiang1– 3 1School of Public Health, Hangzhou Normal University, Hangzhou, 311100, People’s Republic of China; 2Tuberculosis Control ...
Tong E +7 more
doaj +1 more source
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
Drug Design, Development and Therapy, 2016 Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Hu MH, Zheng CL, Gao F
doaj +1 more source
International Journal of Infectious Diseases, 2018 The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ...
Seyeon Park +3 more
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2021 Background Tuberculosis is an infection that has high mortality rate in human as well as in animals if it remains unattained for long time. Scientists are always desirous to discover new molecules against Mycobacterium tuberculosis; one of them is ...
S. J. Rajput, P. J. Vanavi
doaj +1 more source
Prolonged use of bedaquiline in the treatment for MDR-TB in a child
IDCases, 2021 Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months.
Marina F. Gubkina +3 more
doaj +1 more source